Bin Su, Ph.D.
B_SU.jpg
 Title: Professor
 Dept: Chemistry
 Office: SR 327
 Phone: 216-687-9219
 Email: B.SU@csuohio.edu
 Address: 2121 Euclid Ave. SR 327, Cleveland, OH 44115

Courses Taught

Publications


Faculty Only:
Update Profile
 

 
Research Keywords:
Drug development, Cancer, African trypanosomiasis, Synthetic medicinal chemistry, Pharmacokinetic study
 
Education:
Ph.D., Pharmacy, The Ohio State University, 2006
M.S., Medicinal Chemistry, Peking University, 2002
B.S., Medicinal Chemistry, Beijing Medical University, 1996
 
Brief Bio:
Dr.Su graduated from the Ohio State University in Dr. Bob Brueggemeier's group. Then he moved to City of Hope National Medical Center at LA to be further trained in cancer biology and molecular pharmacology related to translational researches by working with Dr. Shiuan Chen. He is well trained in synthetic medicinal chemistry, cancer biology, molecular endocrinology which enriched his expertise in drug design and development. He joined CSU at August 2009 and started his independent academic career. His lab focuses on synthetic medicinal chemistry in anti-cancer and anti-trypanosomiasis drug development.
 
Honors and Awards:
              
2012,2013,2014, 2016, 2017, 2019, 2020 Faculty Merit Recognition Award of Research (CSU); 2014 McNair program, Mentor of the year;  2020 Distinguish Faculty of Teaching (CSU)
 
Research Interests:
Dr.Su's lab focuses on anti-cancer and anti-trypanosomiasis drug development
1. Hsp27 inhibitor development. The expression of heat shock proteins (Hsp) is increased under lethal conditions, which is a typical response when cancer cells are stressed by chemotherapies. Hsp27, a small heat shock protein, shows a very tight correlation with anti-cancer drug resistance. Its over-expression also enhances the oncoprotein such as androgen receptor in glioblastoma. Targeting Hsp27 is a novel strategy for cancer treatment. Our lab has identified lead compounds that inhibit Hsp27 activity, and we current perform lead optimization to improve the pharmacological activity of the compounds.
2. Selective tubulin inhibitors for the treatment of African trypanosomiasis. By collaborating with Dr. Bibo Li at BEGS, we screened the small molecule compound library generated in our lab with T.brucei cells that is the parasite causing African sleeping disease. Interestingly, we identified several lead compounds that selectively inhibited the parasite growth, and did not affect the mammalian cell proliferation. These compounds selectively interfere with parasite tubulin, and do not block the mammalian tubulin function. There is a great potential to develop cheap, easy make drug candidates for the treatment of this Neglected Tropical Disease.  
3. EphA2 is a tyrosine kinase overexpressed in glioblastoma, and it drives the tumor growth and metastasis. By collaborating with Professor Bincheng Wang (CWRU metrohealth hospital), we try to develop inhibitors for this receptor based on Doxazocin as a lead compound. So far, new analogs showed much better activity than the lead compound.
 
Teaching Areas:
Pharmacology, Organic chemistry, Medicinal Chemistry
 
Professional Affiliations:
Member of American Chemical Society
Member of American Association of Pharmaceutical Scientists
 
University Service:
Director of the chemistry undergraduate program
 
Professional Service:
Dr. Su is a reviewer on a routine basis for several journals including Journal of medicinal chemistry, European Journal of medicinal chemistry, ChemMedChem, Medicinal chemistry communication, Current medicinal chemistry, Cancer epidemiology, Tumor biology.
 
Research Grants:
Ongoing Research Support
1. R15(PI: Su, Bin) NIH 1 R15 NS116766-01A1 ($445,500)
Proposal Title: Targeting Androgen Receptor-HSP27 Signaling in Glioblastoma
Project Period Begin Date: 04/1/2021
Project Period End Date: 3/31/2024

2.RO1(PI: Wang, Bingcheng (CWRU), co-I: Su, Bin (CSU)) NIH, 1R01NS09695601
Proposal Title: Targeting EphA2 in Glioblastoma
Project Period Begin Date: 04/01/2016
Project Period End Date: 12/31/2021

Completed grants:

1. R15AI103889-01 Drug development of orally active anti-trypanosomiasis agents
NIH/ NIAIDs 1/2013-6/2016
2. 2R15AI103889-01 Selective tubulin inhibitors with improved cell update for kinetoplastid infections
(Bin Su, PI) 7/1/2016-6/31/2019
Funding Agency: NIAID